<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02033954</url>
  </required_header>
  <id_info>
    <org_study_id>TD 0088 / 04</org_study_id>
    <nct_id>NCT02033954</nct_id>
  </id_info>
  <brief_title>Evaluation of Peripheral EOS for the Peripheral Embolization Treatment to Rapidly OccluDe Venous or Arterial BleEding</brief_title>
  <acronym>OCCLUDE-II</acronym>
  <official_title>PrOspective, MultiCenter Study for the Evaluation of PerformanCe of the ArtVentive Medical Group Peripheral EndoLuminal OcclUsion SystemTM for the Peripheral Embolization Treatment to Rapidly OccluDe Venous or Arterial BleEding - OCCLUDE II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ArtVentive Medical Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ArtVentive Medical Group, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To collect confirmatory data in support of the safety and performance of the ArtVentive
      Medical Group Endoluminal Occlusion System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, non-randomized, multi-center confirmatory observational study for the treatment
      of subjects with the need for vascular occlusion for the following conditions:

        1. Stopping blood loss from a damaged blood vessel from a traumatic vascular injury

        2. Hemorrhage caused by a neoplasia

        3. Neoplastic process (tumor)

        4. Gastrointestinal bleeding

        5. Closing an abnormal blood vessel supplying a vascular anomaly such as arteriovenous
           malformations or an arteriovenous fistula

        6. Interrupting blood supply to an organ or part of an organ for permanent
           devascularization

        7. Devascularization of tissues involved by a neoplastic process either pre-operatively or
           as a palliative measure

        8. Transjugular Intrahepatic Portosystemic Shunt (TIPS)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Acute &amp; 30 days</time_frame>
    <description>Composite of new-onset major device-related adverse event(s) including device embolization beyond targeted treatment area (not therapeutic indication of embolization), need for emergency surgical intervention of the target vessel, or distal embolization (non-device embolization, e.g., particulate matter / plague distal to the device) at 30 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occlusion</measure>
    <time_frame>30 days</time_frame>
    <description>Sustained occlusion at 30 days follow-up.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hemorrhage</condition>
  <condition>Bleeding</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects requiring permanent occlusion of the peripheral vessels for the following
        conditions:

          1. Stopping blood loss from a damaged blood vessel from a traumatic vascular injury

          2. Hemorrhage caused by a neoplasia

          3. Neoplastic process (tumor)

          4. Gastrointestinal bleeding

          5. Closing an abnormal blood vessel supplying a vascular anomaly such as arteriovenous
             malformations or an arteriovenous fistula

          6. Interrupting blood supply to an organ or part of an organ for permanent
             devascularization

          7. Devascularization of tissues involved by a neoplastic process either pre-operatively
             or as a palliative measure.

          8. Transjugular Intrahepatic Portosystemic Shunt (TIPS)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged ≥18 to ≤75 years.

          2. Subject with target vessels of 3.0 mm to 12 mm in diameter.

          3. Subject is able and willing to comply with all study requirements, including the
             required study follow-up visits.

          4. Subject or subject's legal representative have been informed of the nature of the
             study, agrees to participate and has signed the consent form. In the event of
             emergency procedure and subject and/or legal representative is unable to provide
             consent prior to study enrollment, consent will be obtained at earliest possible time
             following procedure for consent to continue to participate in the study.

        Exclusion Criteria:

          1. Subject has a known allergy to iodinated contrast for which they cannot be adequately
             premedicated.

          2. Subjects in whom venography or arteriography is contraindicated.

          3. Subjects with known hypersensitivity or contraindication to nickel or nitinol.

          4. Subject is pregnant or breastfeeding.

          5. Any clinical evidence that the investigator feels would place the subject at increased
             risk with the deployment of the device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Mahnken, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Giessen und Marburg (UKGM) Klinik für diagnostische und</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leon Rudakov, PhD</last_name>
    <phone>+1 (760) 471-7700</phone>
    <email>leonrudakov@artventivemedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum Klagenfurt am Worthersee</name>
      <address>
        <city>Klagenfurt</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Hausegger, Prof. Dr.</last_name>
      <phone>+43 463 538 38 503</phone>
      <email>Klaus.hausegger@kabeg.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Schwestern Linz Betriebsgesellschaft m.b.H.</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Waldenberger, Prof Dr</last_name>
      <phone>+43 73276777346</phone>
      <email>Peter.waldenberger@bhs.at</email>
    </contact>
    <investigator>
      <last_name>Peter Waldenberger, Prof Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Geert Maleux, Prof Dr</last_name>
      <phone>+32 16 34 37 82</phone>
      <email>geert.maleux@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Geert Maleux, Prof Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Carl Gustav Carus Institut</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralf Hoffmann, PD Dr.</last_name>
      <phone>+49 351 - 458 2259</phone>
      <email>radiologie@uniklinikum--dresden.de</email>
    </contact>
    <investigator>
      <last_name>Ralf Hoffmann, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universität Leipzig - Department für Bildgebung und Strahlenmedizin</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Moche, Dr.</last_name>
      <phone>+49 341 9717558</phone>
      <email>Michael.moche@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Giessen und Marburg (UKGM) Klinik für diagnostische und</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Mahnken, Prof Dr</last_name>
      <phone>+49 6421 58-66231</phone>
      <email>m.treitl@med.unimuenchen.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Mahnken, Prof Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universität München, Campus Innenstadt, Interventionelle Radiologie</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcus Treitl, Prof dr</last_name>
      <phone>+49 89-5160-9271</phone>
      <email>m.treitl@med.unimuenchen.de</email>
    </contact>
    <investigator>
      <last_name>Marcus Treitl, Prof Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Venbrux AC, Rudakov L, Plass A, Emmert MY, Ebner A. A new occlusion device: application of the ArtVentive endoluminal occlusion system (EOS)--first in human clinical trial. Cardiovasc Intervent Radiol. 2014 Feb;37(1):85-93. doi: 10.1007/s00270-013-0626-y. Epub 2013 May 24.</citation>
    <PMID>23703667</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2014</study_first_submitted>
  <study_first_submitted_qc>January 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2014</study_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Embolization</keyword>
  <keyword>Hemorrhage</keyword>
  <keyword>TIPS</keyword>
  <keyword>GI Bleeding</keyword>
  <keyword>AV Fistula</keyword>
  <keyword>AV Malformation</keyword>
  <keyword>Traumatic Vascular Injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

